My guess for RR: - Kevetrin trial update - Leo u
Post# of 72447
Posted On: 08/27/2013 9:27:17 AM
My guess for R&R:
- Kevetrin trial update - Leo uses the same language as we've heard in the past to keep it somewhat vague "pleased with the results to date considering the doses to date" - something along those lines. I think aside from that, we get a cohort # and dosing level update and thats about it, the wait for P21 continues. I'd love to be wrong.
- Prurisol - I just have this feeling that they are lining everything up to announce that dosing has started that very day to generate more buzz and excitement coming out of the conference . Perhaps a trial start announcement, and providing info on the trial itself would be very newsworthy and make some waves.
Other than that, I think it will be a fairly standard rundown of the company ongoings - the Aspire backing, MD Anderson studies, Bologna, uplisting plans, etc etc, also probably a mention for KM391, as I believe we may not be too far off from hearing some developments regarding this compound.
But of course there's the wild cards, the new leukemia drug, "other corporate developments".
But IMO, one of the biggest potential events that could really get people talking is the announcement or even appearance of a newly appointed independent director that shows investors Leo is serious about uplisting and it is in the works, with support from a big name to oversee it. I just have this feeling that just like we are blown away with our scientific advisory team, we will get some real power hitters on our corporate governance team as well. What if it's someone very highly respected and a "household name" in the biotech space? This could boost confidence for company outlook dramatically, and the subsequent SP along with it.
I'm sure I missed a few pertinent points, just rambling here. Less than 2 weeks to go.
Also very much looking forward to hearing from the group on the ground floor that will be attending, just to get the feel and overall pulse of the presentation and how it seemed to be recieved. I appreciate all those who are attending, and look forward to hearing your thoughts on the entire event! Thank you in advance
- Kevetrin trial update - Leo uses the same language as we've heard in the past to keep it somewhat vague "pleased with the results to date considering the doses to date" - something along those lines. I think aside from that, we get a cohort # and dosing level update and thats about it, the wait for P21 continues. I'd love to be wrong.
- Prurisol - I just have this feeling that they are lining everything up to announce that dosing has started that very day to generate more buzz and excitement coming out of the conference . Perhaps a trial start announcement, and providing info on the trial itself would be very newsworthy and make some waves.
Other than that, I think it will be a fairly standard rundown of the company ongoings - the Aspire backing, MD Anderson studies, Bologna, uplisting plans, etc etc, also probably a mention for KM391, as I believe we may not be too far off from hearing some developments regarding this compound.
But of course there's the wild cards, the new leukemia drug, "other corporate developments".
But IMO, one of the biggest potential events that could really get people talking is the announcement or even appearance of a newly appointed independent director that shows investors Leo is serious about uplisting and it is in the works, with support from a big name to oversee it. I just have this feeling that just like we are blown away with our scientific advisory team, we will get some real power hitters on our corporate governance team as well. What if it's someone very highly respected and a "household name" in the biotech space? This could boost confidence for company outlook dramatically, and the subsequent SP along with it.
I'm sure I missed a few pertinent points, just rambling here. Less than 2 weeks to go.
Also very much looking forward to hearing from the group on the ground floor that will be attending, just to get the feel and overall pulse of the presentation and how it seemed to be recieved. I appreciate all those who are attending, and look forward to hearing your thoughts on the entire event! Thank you in advance
(0)
(0)